• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience.

作者信息

Porrazzo Marika, Moscato Tiziana, Sapienza Giuseppe, Accardi Fabrizio, Patti Caterina, Cangialosi Clotilde, Costanza Carmelo, Bono Roberto, Tringali Stefania, Rotolo Cristina, Gigliotta Emilia, Rizzuto Andrea, Ingrascè Manuela Giuseppa, Butera Giulia, Di Noto Laura, Santoro Alessandra, Marfia Anna, Botta Cirino, Siragusa Sergio, Martino Massimo, Castagna Luca

机构信息

Onco-Hematology Unit, Azienda Ospedaliera Riunita (AOR) Villa Sofia-Vincenzo Cervello, Palermo.

Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria.

出版信息

Haematologica. 2025 Mar 1;110(3):791-794. doi: 10.3324/haematol.2024.286332.

DOI:10.3324/haematol.2024.286332
PMID:39479867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11873712/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69bb/11873712/d5c633f4b547/110791.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69bb/11873712/d5c633f4b547/110791.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69bb/11873712/d5c633f4b547/110791.fig1.jpg

相似文献

1
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience.达雷妥尤单抗/硼替佐米/沙利度胺联合地塞米松诱导治疗对符合移植条件的新诊断多发性骨髓瘤患者免化疗干细胞动员的影响：一项多中心真实世界研究
Haematologica. 2025 Mar 1;110(3):791-794. doi: 10.3324/haematol.2024.286332.
2
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗，随后进行达雷妥尤单抗维持或观察治疗，适用于适合移植的新诊断多发性骨髓瘤：CASSIOPEIA 随机对照 3 期试验的长期随访。
Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15.
3
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.在新诊断的多发性骨髓瘤患者中，硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗和自体干细胞移植治疗后，用达雷妥尤单抗或观察进行维持治疗（CASSIOPEIA）：一项开放标签、随机、3 期试验。
Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13.
4
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.EMA 审查达雷妥尤单抗（Darzalex）治疗新诊断为多发性骨髓瘤的成年患者。
Oncologist. 2020 Dec;25(12):1067-1074. doi: 10.1002/onco.13554. Epub 2020 Oct 16.
5
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
6
Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.关于皮下注射达雷妥尤单抗联合硼替佐米、沙利度胺和地塞米松用于新诊断的适合移植的多发性骨髓瘤患者的真实世界数据。
Ann Hematol. 2025 Apr 30. doi: 10.1007/s00277-025-06365-3.
7
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于符合移植条件的新诊断多发性骨髓瘤患者（CASSIOPEIA）：一项随机、开放标签、3期试验的健康相关生活质量结果
Lancet Haematol. 2020 Dec;7(12):e874-e883. doi: 10.1016/S2352-3026(20)30356-2.
8
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、硼替佐米、沙利度胺和地塞米松方案与硼替佐米、环磷酰胺和地塞米松方案用于新诊断多发性骨髓瘤患者自体干细胞采集的比较
Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct.
9
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.达雷妥尤单抗：一种适合移植的新诊断多发性骨髓瘤联合治疗药物的评价。
Drugs. 2020 Sep;80(14):1455-1464. doi: 10.1007/s40265-020-01385-x.
10
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.

本文引用的文献

1
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.抗 CD38 单克隆抗体可损害多发性骨髓瘤患者 CD34+细胞的动员，并影响其集落形成能力。
Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.
2
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.一项关于新型药物治疗多发性骨髓瘤患者用环磷酰胺联合粒细胞集落刺激因子和按需使用plerixafor进行造血干细胞动员的前瞻性、多中心研究。
Haematologica. 2024 May 1;109(5):1525-1534. doi: 10.3324/haematol.2023.284023.
3
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
达雷妥尤单抗、硼替佐米、沙利度胺和地塞米松方案与硼替佐米、环磷酰胺和地塞米松方案用于新诊断多发性骨髓瘤患者自体干细胞采集的比较
Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct.
4
Insight into the mechanism of CD34 cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.深入了解接受抗CD38治疗的多发性骨髓瘤患者中CD34细胞动员受损的机制。
Br J Haematol. 2024 Apr;204(4):1439-1449. doi: 10.1111/bjh.19141. Epub 2023 Oct 9.
5
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.达雷妥尤单抗对多发性骨髓瘤患者自体干细胞移植中干细胞动员和采集、植入和移植后早期并发症的影响。
Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1.
6
Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma.在多发性骨髓瘤中，基于达雷妥尤单抗的诱导治疗后，更高剂量的环磷酰胺可实现最佳的干细胞采集。
Haematologica. 2023 Dec 1;108(12):3502-3505. doi: 10.3324/haematol.2023.283452.
7
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.接受基于达雷妥尤单抗诱导治疗的多发性骨髓瘤患者的干细胞动员：一项真实世界经验
Transplant Cell Ther. 2023 May;29(5):340.e1-340.e4. doi: 10.1016/j.jtct.2023.02.013. Epub 2023 Feb 19.
8
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
9
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合最小残留病灶反应适应性治疗新诊断多发性骨髓瘤。
J Clin Oncol. 2022 Sep 1;40(25):2901-2912. doi: 10.1200/JCO.21.01935. Epub 2021 Dec 13.
10
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.